ArticleNeuro-oncology advances

Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma.

Santiago Cabezas-Camarero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.